You searched for "interview"

1643 results found

Highlights from The RCOphth Annual Congress 2023

Check in here for live updates and media from the RCOphth Annual Congress 2023 being held in Birmingham's ICC between 22-25 May.

Thank you, Baljean Dhillon. Welcome onboard, Peter Cackett.

As our Co-editor of over 11 years, Baljean Dhillon, passes the torch, Peter Cackett steps up to take on the role.

RNIB working with games studios to make VR more accessible

Abertay University and RNIB launch toolkit to make extended reality experiences more accessible for blind and partially sighted people. The new guidance launched in December 2025 will support accessible design in games and immersive experiences for blind and partially sighted...

Martial arts mum fights for inclusive employment

A visually impaired mum in West Lothian is calling for more accessible and inclusive employment for people with sight loss. Amanda Whitfield (35) recently won medals alongside her five-year-old daughter in mixed martial arts, after taking part in local family...

High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema

The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration

This is a sub-group study of double masked review of patients randomised to different dosages and treatment frequency compared between aflibercept and ranibizumab treatment. This is to evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with...

Happy hour

Welcome Eye News Aug/Sep 2023, your bi-monthly tonic for a much-needed happy hour. In the current climate of challenge across all fronts, there’s no better time to reach out for the professional equivalent of a cheery cup in the company...

100% Ophthalmology Programme Insights

We spoke to some of the Eye News family about their upcoming presentations at 100% Opthalmology, 24–26 February 2024, ExCeL London, UK.

On reflection

Welcome one and all to our festive Eye News Dec/Jan 2024. The arrow of time has flown through 2023, landing us at the year’s end, but not before Santa brings you this special delivery. Aside from the partying and generally...

Post hoc analysis of the CANTREAT randomised trial

CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...

The fragile p-value

Abdus Samad Ansari explores the limitation of the p-value and the application of the fragility index in clinical trials. Clinical trials and tribulations? The restoration of vision or more purely the gift of sight is an aspect of care that...

Clinical trial investigates ‘Light Touch’ approach to wet AMD treatment

A clinical trial led by NIHR Moorfields Clinical Research Facility will explore a new ‘light-touch’ treatment approach for patients with neovascular age-related macular degeneration (wet AMD) that could result in fewer injections and reduced number of clinic visits. Funded by...